Brookline tells investors in a research note that IceCure Medical's disclosure of a 70% boost in the U.S. active commercial install base of ProSense for breast cancer cryoablation is "very encouraging," as evidence is rising in advance of reimbursement, confirming that there is a segment of the patient population that is willing to pay out-of-pocket to access the procedure. The firm, which has a Buy rating and $73.50 price target on the shares post-stock split, says business is "moving in the right direction."
